Industry News

Join WhatsApp Channel 

Crack GPAT — Prepare for GPAT Online
  • Lupin acquires Huminsulin from Lilly to Enhance Diabetes Portfolio
    1 January 2025

    Lupin acquires Huminsulin from Lilly to Enhance Diabetes Portfolio

    Global pharma major Lupin Limited announced the acquisition of Huminsulin® in India from Eli Lilly and Company to further enhance its diabetes portfolio. Lupin has been marketing the Huminsulin range of products comprising of Insulin Human, including Huminsulin R, Huminsulin NPH, Huminsulin 50/50, and Huminsulin 30/70, through existing Distribution and Promotion Agreements with Lilly, India.
  • 27 December 2024
    Akums signs agreement of Rs. 1760 crore to supply pharmaceuticals in Europe

    Akums Drugs and Pharmaceuticals has entered into an agreement with one of Leading Global Pharma Company for Manufacture and Supply of selected pharmaceutical formulations in the European Market. Akums group will manufacture and supply Oral Liquid Formulation to be marketed in multiple European countries.

  • 19 December 2024
    SPARC announces Signing of Binding Letter of Intent with UCSF and Tiller Therapeutics for Pre-clinical Oncology Asset and Associated Intellectual Property
    Sun Pharma Advanced Research Company Ltd announced the signing of a binding Letter of Intent with the University of California, San Francisco, through the office of OTMA, and Tiller Therapeutics Inc. to license SPARC’s rights in the joint intellectual property held between SPARC and UCSF for pre-clinical oncology asset along with associated IP. The LOI outlines the key terms of license and rights for development and commercialization by Tiller.
  • 13 December 2024
    IBRANCE® in combination with Standard-of-Care therapies extends survival by over 15 months
    Pfizer Inc. and Alliance Foundation Trials, LLC announced results from the Phase 3 PATINA trial demonstrating that the addition of IBRANCE palbociclib to current standard-of-care first-line maintenance therapy following induction chemotherapy resulted in statistically significant and clinically meaningful improvement in progression-free survival by investigator assessment in patients with hormone receptor-positive
  • 12 December 2024
    Cipla receives approval for distribution and marketing of inhaled insulin in India
    Cipla Limited announced that it has obtained regulatory approval from Central Drugs Standard Control Organisation for the exclusive distribution and marketing of Afrezza insulin human Inhalation Powder in India. Afrezza, a product created and manufactured by MannKind Corporation
  • 29 November 2024
    Dr. Reddy's launches Toripalimab in India
    Toripalimab is a New Biological Entity. It is the only immuno-oncology drug approved by various regulatory authorities around the world such as the United States Food and Drug Administration, European Medicines Agency, Medicines and Healthcare products Regulatory Agency, and others for the treatment of adults with recurrent or metastatic nasopharyngeal carcinoma.
  • 29 November 2024
    Abbott launches 14 valent Pneumococcal Conjugate Vaccine (PCV-14) That Offers Broadest Protection for Children Against Pneumococcal Bacterial Infections

    Abbott, the global healthcare leader, announced today the launch of its Pneumococcal Conjugate Vaccine, PneumoShield 14, for children over 6 weeks of age. Abbott’s PCV-14 valent (Pneumococcal Conjugate Vaccine), offers broad protection, covering the highest number of serotypes, or strains, as compared to existing PCV-10 and PCV-13 vaccines.

  • 22 November 2024
    European Commission Approves Pfizer’s HYMPAVZI (marstacimab)
    Pfizer Inc announced that the European Commission has granted marketing authorization for HYMPAVZI marstacimab for the routine prophylaxis of bleeding episodes in patients 12 years of age and older weighing at least 35 kg with severe hemophilia A
  • 21 November 2024
    Syndax announces FDA approval of Revuforj (revumenib)
    Syndax Pharmaceuticals announced that the U.S. Food and Drug Administration has approved Revuforj revumenib as the first and only menin inhibitor for the treatment of relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene KMT2A translocation in adult and pediatric patients one year and older.
  • 15 November 2024
    Sandoz receives European Commission approval for Afqlir® (aflibercept), further strengthening leading biosimilar portfolio

    Sandoz the global leader in generic and biosimilar medicines, today announced that the European Commission (EC) has granted marketing authorization for Afqlir® (aflibercept) 2 mg vial kit and pre-filled syringe for intravitreal injection, a biosimilar to reference medicine Eylea®. Afqlir® is indicated to treat various retinal diseases, including neovascular age-related macular degeneration (nAMD), aiming to prevent disease-related blindness.

Subscribe to Industry News